ReviewFrontiers in immunology2022

Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.

Tomoko Matsuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.